Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Abstract Background The oral IP receptor agonist selexipag is approved for the long-term treatment of pulmonary arterial hypertension (PAH). Treatment interruptions should be avoided due to the progressive nature of the disease. An intravenous (IV) formulation of selexipag was developed to provide a...

Full description

Bibliographic Details
Main Authors: Hans Klose, Kelly M. Chin, Ralf Ewert, Henning Gall, Joseph Parambil, David Poch, Hans-Jürgen Seyfarth, Lene N. Axelsen, Shu-Fang Hsu Schmitz, Claudia Stein, Ioana R. Preston
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Respiratory Research
Subjects:
Selexipag
Pulmonary arterial hypertension
Pharmacokinetics
Treatment interruptions
Intravenous
Online Access:https://doi.org/10.1186/s12931-020-01594-8

Internet

https://doi.org/10.1186/s12931-020-01594-8

Similar Items